Is there a role for budesonide (ileal‑release) or mesalamine (5‑ASA) in managing an isolated non‑healing, non‑progressive ulcer of the terminal ileum?

Ileal-Release Budesonide 9 mg Daily for 8 Weeks is the Preferred First-Line Treatment for an Isolated Non-Healing Terminal Ileal Ulcer

For an isolated, non-healing, non-progressive terminal ileal ulcer, ileal-release budesonide 9 mg once daily for 8 weeks is the recommended treatment, as it specifically targets ileocaecal disease with proven efficacy and a favorable safety profile. Mesalamine (5-ASA) has limited evidence for isolated ileal disease and is not recommended as first-line therapy for this indication.

Rationale Based on Guidelines and Evidence

Budesonide for Ileocaecal Disease

The British Society of Gastroenterology (2019) provides the strongest guideline support: "mild to moderate ileocaecal Crohn's disease can be treated with ileal-release budesonide 9 mg once daily for 8 weeks to induce remission" 1. This recommendation carries strong evidence (GRADE: strong recommendation, high-quality evidence) and is specifically designed for disease localized to the terminal ileum and ascending colon.

The ECCO guidelines (2020) reinforce this, recommending budesonide specifically for "active mild-to-moderate Crohn's disease limited to the ileum and/or ascending colon" 2. The ileal-release formulation delivers the drug precisely where your patient's ulcer is located, achieving high local concentrations with minimal systemic absorption.

Clinical Efficacy Data

Budesonide 9 mg daily achieves:

• 51% remission rate at 8 weeks in ileocaecal disease 1
• Significantly superior to placebo (RR: 1.93; 95% CI: 1.37–2.73) 2
• Better tolerated than systemic corticosteroids with fewer side effects 1

The drug should be tapered over 1-2 weeks after remission is achieved 1.

Why Not Mesalamine?

The evidence against mesalamine for isolated ileal disease is compelling:

1. Lack of efficacy in ileal disease: The 2021 AGA guidelines on moderate-to-severe Crohn's disease state: "We recommend against the use of 5-ASA or sulfasalazine over no treatment for the induction or maintenance of remission" (strong recommendation, moderate certainty evidence) 3. While this addresses moderate-to-severe disease, the principle applies to isolated ileal involvement.

2. Inferior to budesonide: A head-to-head trial showed budesonide achieved 69% remission at 8 weeks versus 45% with mesalamine (P=0.001), and 62% versus 36% at 16 weeks (P<0.001) in ileocolonic Crohn's disease 4.

3. Formulation limitations: Most mesalamine formulations are designed for colonic delivery. While some pH-dependent formulations release in the terminal ileum 5, they are optimized for ulcerative colitis, not isolated ileal pathology.

4. The one exception: A 2022 RCT specifically studied "nonspecific terminal ileal ulcers" and found no significant difference between mesalamine 4 g/day and observation alone at 6 or 12 months (endoscopic remission: 73.2% vs 61.0%, p=0.24) 6. This suggests that for truly isolated, non-progressive ileal ulcers, mesalamine offers minimal benefit over natural history.

Practical Implementation

Treatment Protocol:

• Budesonide 9 mg once daily (ileal-release formulation)
• Duration: 8 weeks
• Taper over 1-2 weeks after achieving remission 1
• Swallow whole with water; do not crush or chew 7
• Avoid grapefruit juice during therapy 7

When to Consider Mesalamine:

Mesalamine has no established role for isolated terminal ileal ulcers based on current evidence. The 2004 BSG guidelines mention that "high dose mesalazine (4 g/daily) may be sufficient initial therapy" for mild ileocolonic Crohn's disease 8, but this is for ileocolonic (not isolated ileal) disease and represents older, less robust evidence.

Important Caveats:

1. Exclude other diagnoses first: Before treating empirically, ensure you've ruled out:

   • Crohn's disease (through comprehensive evaluation including cross-sectional imaging)
   • Intestinal tuberculosis
   • NSAID-induced ulceration
   • Malignancy

2. Monitor for progression: The 2022 RCT found that nonspecific terminal ileal ulcers showed no progression to Crohn's disease or tuberculosis over 12 months 6. However, maintain surveillance.

3. Systemic corticosteroid effects: While budesonide has high first-pass metabolism, it can still cause hypercorticism and adrenal suppression 7. Monitor for systemic effects, especially if prolonged use is needed.

4. If budesonide fails: Consider:

   • Reassessing the diagnosis
   • Escalating to systemic corticosteroids (prednisolone 40 mg daily) 1
   • Evaluating for immunosuppressive therapy if this represents early Crohn's disease

Safety Profile:

Budesonide demonstrates fewer adverse events than systemic corticosteroids 1, 4 and is generally well-tolerated. The FDA label notes potential for adrenal suppression, immunosuppression, and rare Kaposi's sarcoma with chronic use 7, but these risks are substantially lower than with conventional steroids.

The bottom line: Budesonide 9 mg daily for 8 weeks is the evidence-based choice for isolated terminal ileal ulcers. Mesalamine lacks supporting data for this specific indication and should not be used.